Contrast agent firms Bayer Schering Pharma and Epix Pharmaceuticals have agreed to end their marketing partnership for the Vasovist blood-pool MR angiography agent that Epix developed, the Lexington, MA-based firm said.
Bayer Schering Pharma of Berlin will transfer Vasovist rights to Epix by December 31 of this year; the collaboration agreement between the two companies will end March 1, 2009. Until that time, Bayer Schering Pharma will continue to provide Vasovist to the 19 countries where the agent is currently marketed.
Related Reading
Epix to form technology advisory board, August 14, 2008
Epix's Q2 results show boosted revenues, August 7, 2008
Epix secures equity financing, August 5, 2008
Epix CEO resigns, July 28, 2008
Epix wins South Korean approval of Vasovist, July 10, 2008
Copyright © 2008 AuntMinnie.com
